HC Wainwright Analysts Lower Earnings Estimates for ETON

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities researchers at HC Wainwright reduced their Q2 2025 EPS estimates for shares of Eton Pharmaceuticals in a research report issued on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.08 per share for the quarter, down from their previous forecast of $0.17. HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.57 EPS, FY2027 earnings at $1.85 EPS, FY2028 earnings at $2.87 EPS and FY2029 earnings at $3.74 EPS.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The company had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million.

A number of other equities analysts have also weighed in on ETON. Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday. B. Riley reaffirmed a “buy” rating and issued a $24.00 target price (up from $21.00) on shares of Eton Pharmaceuticals in a research note on Wednesday.

Eton Pharmaceuticals Trading Down 3.8 %

Shares of NASDAQ ETON opened at $14.22 on Friday. The firm has a market cap of $370.45 million, a PE ratio of -64.64 and a beta of 1.37. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41. The company has a fifty day moving average price of $15.58 and a 200 day moving average price of $11.58.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Nantahala Capital Management LLC boosted its stake in shares of Eton Pharmaceuticals by 12.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company’s stock worth $14,898,000 after buying an additional 119,750 shares during the last quarter. Westside Investment Management Inc. boosted its stake in shares of Eton Pharmaceuticals by 5.7% during the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock worth $3,711,000 after buying an additional 33,275 shares during the last quarter. Mink Brook Asset Management LLC acquired a new position in shares of Eton Pharmaceuticals during the 4th quarter worth about $6,071,000. Cannell Capital LLC acquired a new position in shares of Eton Pharmaceuticals during the 4th quarter worth about $5,079,000. Finally, Parkman Healthcare Partners LLC boosted its stake in shares of Eton Pharmaceuticals by 6.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company’s stock worth $3,688,000 after buying an additional 16,664 shares during the last quarter. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.